Buda Juice Targets NYSE Listing with 'UltraFresh' IPO

Ticker: BUDA · Form: S-1/A · Filed: Dec 18, 2025 · CIK: 2079720

Sentiment: mixed

Topics: IPO, Beverage Industry, Emerging Growth Company, Cold-Pressed Juice, NYSE Listing, S-1/A Filing, Food & Beverage

Related Tickers: BUDA

TL;DR

**BUDA's IPO is a high-risk, high-reward bet on disrupting the 'fresh' juice market with its 'UltraFresh' tech, but watch out for listing approval and market acceptance.**

AI Summary

Buda Juice, LLC, soon to be Buda Juice, Inc. (BUDA), is launching an IPO of 2,666,667 shares of common stock at an estimated price between $7.50 and $9.00 per share. The company is pioneering the 'UltraFresh™' juice category, focusing on cold-crafted, never heat-treated or HPP-processed citrus-based beverages. Initially expanding through retail stores since 2014, Buda Juice strategically pivoted to selling to established retailers to achieve broader impact. The offering is contingent upon successful listing on the NYSE under the symbol 'BUDA'. Key risks include the lack of a prior public market for its common stock and the inherent risks associated with an emerging growth company. The company aims to redefine fresh juice standards and expand the refrigerated juice category by providing clean, safe, and nutritious beverages at scale.

Why It Matters

Buda Juice's IPO could disrupt the refrigerated juice market by introducing its 'UltraFresh™' category, challenging established players who rely on pasteurization or HPP. For investors, this represents an opportunity in a potentially high-growth segment, but also carries the risks of an emerging growth company in a competitive beverage industry. Employees and local farmers, particularly in Texas, could see increased stability and demand as the company scales its operations and sourcing. Customers stand to benefit from a new option for genuinely fresh, nutrient-rich juices, potentially shifting consumer expectations for 'fresh' products in grocery stores.

Risk Assessment

Risk Level: high — The offering involves a high degree of risk, as explicitly stated in the S-1/A filing under 'Investing in our Common Stock involves a high degree of risk.' The company is an 'emerging growth company' and there has been 'no public market for our Common Stock' prior to the offering, indicating significant market uncertainty. Furthermore, the 'closing of this Offering is contingent upon the successful listing of our Common Stock on NYSE,' adding a critical contingency risk.

Analyst Insight

Investors should carefully evaluate Buda Juice's business model and market potential against the significant risks, particularly the lack of operating history as a public company and the contingent NYSE listing. Consider a small, speculative position only if you have a high-risk tolerance and believe in the long-term viability of their 'UltraFresh' concept.

Financial Highlights

revenue
$11.2 million
revenue Growth
+100.0%

Revenue Breakdown

SegmentRevenueGrowth
Total Revenue$11.2 million+100.0%

Key Numbers

Key Players & Entities

FAQ

What is Buda Juice's core business model?

Buda Juice is pioneering the 'UltraFresh™' juice category, offering cold-crafted citrus-based drinks that are never heat-treated or HPP-processed. They initially expanded through retail stores but pivoted to selling to established retailers, focusing on high-tech automation and maintaining a cold-chain from orchard to shelf.

What is the estimated IPO price range for Buda Juice shares?

The estimated initial public offering price for Buda Juice's common stock is between $7.50 and $9.00 per share. The prospectus assumes an initial public offering price of $7.50 for certain financial data calculations.

Who is the CEO of Buda Juice?

Horatio Lonsdale-Hands is the Co-Founder and Chief Executive Officer of Buda Juice, LLC, and will continue in this role for Buda Juice, Inc. after the conversion. He emphasizes the company's commitment to 'RAW.ORGANIC.REAL.' products.

What are the primary risks associated with investing in Buda Juice?

Investing in Buda Juice involves a high degree of risk, including the absence of a prior public market for its common stock, its status as an 'emerging growth company' with reduced reporting requirements, and the contingency of the offering on successful NYSE listing approval.

How many shares is Buda Juice offering in its IPO?

Buda Juice, Inc. is registering 2,666,667 shares of common stock to be offered in its initial public offering. Additionally, the underwriter has a 45-day option to purchase up to an additional 400,000 shares to cover over-allotments.

What is the significance of the 'Conversion' mentioned in the S-1/A filing for Buda Juice?

The 'Conversion' refers to Buda Juice, LLC's plan to convert from a Texas limited liability company into a Delaware corporation named Buda Juice, Inc. immediately before the IPO's closing. This is a statutory process to facilitate the public offering.

When did Buda Juice begin its operations?

Buda Juice began its journey with informal taste tests and opened its first kiosk inside a coffee shop in Plano, Texas, in 2014. This marked the start of its expansion through its own retail stores.

What is Buda Juice's strategy for growth?

Buda Juice plans to achieve scalable growth through its Buda Fresh and private-brand offerings across multiple channels, geographies, and formats. They aim to expand the refrigerated juice category by helping retailers evolve to the next generation of freshness, driving grocery store traffic.

What is the exercise price for the underwriter warrants for Buda Juice?

The underwriter warrants for Buda Juice are exercisable at a price of $9.375 per share. This price is set at 125% of the assumed initial public offering price of $7.50 per share.

What is Buda Juice's vision for the future?

Buda Juice's vision is to make UltraFresh™ juice the new standard, providing clean beverages in every grocery store across the U.S., without compromise on safety, taste, or nutrients. They believe they are expanding the refrigerated juice category itself.

Risk Factors

Industry Context

Buda Juice operates in the refrigerated juice and beverage market, a segment characterized by increasing consumer demand for healthier, fresher, and minimally processed options. The company is carving out a niche with its 'UltraFresh™' category, differentiating itself from traditional pasteurized juices and shelf-stable alternatives. Key trends include the growth of functional beverages, demand for transparency in ingredients, and the expansion of cold chain logistics to maintain product integrity.

Regulatory Implications

As a food producer, Buda Juice is subject to federal, state, and local regulations concerning food safety, labeling, and manufacturing practices. Compliance with agencies like the FDA is paramount. The company's 'never heat-treated' claim requires robust internal controls and adherence to standards to avoid misbranding or safety issues.

What Investors Should Do

  1. Evaluate the scalability of the cold chain model.
  2. Analyze competitive positioning within the 'UltraFresh™' niche.
  3. Assess the financial viability and path to profitability.
  4. Consider the risks associated with an emerging growth company.

Key Dates

Glossary

UltraFresh™
Buda Juice's proprietary category of cold-crafted, never heat-treated or HPP-processed citrus-based beverages. (Defines the company's unique selling proposition and product differentiation in the juice market.)
Cold Chain Platform
A system that maintains continuous temperature control (35°F) from production to the retail shelf, ensuring product freshness and safety. (Crucial to the 'UltraFresh™' promise, enabling longer shelf life while preserving quality.)
HPP-processed
High-Pressure Processing, a method used to preserve food and beverages without heat, often used to extend shelf life. (Buda Juice explicitly differentiates its products by stating they are *not* HPP-processed, emphasizing a 'fresher' alternative.)
CAGR
Compound Annual Growth Rate, a measure of average annual growth over a specified period longer than one year. (Used to quantify the company's consistent revenue growth, showing a 41.8% CAGR from 2022 to 2024.)
Par Value
The nominal value assigned to a share of stock by the company's charter, often a very small amount. (Indicates the minimum legal capital per share; in this case, $0.001, highlighting that most of the IPO proceeds will be capital surplus.)
Underwriter Warrants
Options granted to the underwriters of an IPO, allowing them to purchase shares at a specified price, typically as compensation. (Represents potential dilution for common shareholders if exercised; here, 266,667 shares at $9.375.)

Year-Over-Year Comparison

This S-1/A filing provides updated financial information, notably showing revenue growth from $5.6 million in 2022 to $11.2 million in 2024, indicating a significant increase in sales. The filing also elaborates on the company's strategic expansion plans, including new facility locations in South Carolina and Arizona/Nevada, which were likely not detailed in previous filings. New risk factors related to the IPO process itself, such as the NYSE listing contingency, are also introduced.

Filing Stats: 4,304 words · 17 min read · ~14 pages · Grade level 14.8 · Accepted 2025-12-17 18:26:19

Key Financial Figures

Filing Documents

USE OF PROCEEDS

USE OF PROCEEDS 32 DIVIDEND POLICY 33 CAPITALIZATION 34

DILUTION

DILUTION 35 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 36

BUSINESS

BUSINESS 46 MANAGEMENT 55 EXECUTIVE AND DIRECTOR COMPENSATION 62 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 64 PRINCIPAL STOCKHOLDERS 65

DESCRIPTION OF CAPITAL STOCK

DESCRIPTION OF CAPITAL STOCK 66 SHARES ELIGIBLE FOR FUTURE SALE 69 MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES TO NON-U.S. HOLDERS OF OUR COMMON STOCK 70

UNDERWRITING

UNDERWRITING 74 LEGAL MATTERS 77 EXPERTS 77 WHERE YOU CAN FIND MORE INFORMATION 77 INDEX TO FINANCIAL STATEMENTS F-1 i Neither we nor the underwriter have authorized anyone to provide any information or to make any representations other than those contained in this prospectus or in any free writing prospectus prepared by or on behalf of us or to which we have referred you. We take no responsibility for and can provide no assurance as to the reliability of any other information that others may give you. This prospectus is an offer to sell only the shares of Common Stock offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. The information contained in this prospectus or in any applicable free writing prospectus is current only as of its date, regardless of its time of delivery or any sale of our Common Stock. Our business, financial condition, results of operations and prospects may have changed since that date. For investors outside the United States: Neither we nor the underwriter have done anything that would permit this Offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the Offering of the shares of Common Stock and the distribution of this prospectus outside the United States. This prospectus contains forward-looking statements that are subject to a number of risks and uncertainties, many of which are beyond our control. See “Risk Factors” and “Special Note Regarding Forward-Looking Statements.” ii ABOUT THIS PROSPECTUS Except where the context otherwise requires or where otherwise indicated throughout this registration statement, the terms “Buda Juice, LLC,” “Buda Juice, Inc.,” “Buda Juice,&rd

financial statements and the related notes included elsewhere in this prospectus, before making an investment decision

financial statements and the related notes included elsewhere in this prospectus, before making an investment decision. If our listing application is not approved by the New York Stock Exchange (“NYSE”), we will not be able to consummate the Offering. Overview Buda Juice is pioneering the UltraFresh TM juice category through our end-to-end cold chain platform that delivers always cold, freshly crafted juice, lemonades and wellness shots to grocery retailers in Texas. We bridge the gap between shelf-stable products and operationally challenging in-store juicing, enabling any retailer to offer truly fresh and safe juice without infrastructure investment or operational complexity. Our breakthrough lies in solving the industry’s fundamental challenge: delivering UltraFresh TM quality on a retail scale. We maintain continuous 35°F temperature control from fruit to shelf, delivering products with 8-12 day shelf life - long enough for retail distribution yet fresh enough to preserve authentic taste. This eliminates the traditional tradeoffs between shelf life, flavor, and nutrient quality in the industry. We have validated our model through strong financial performance, growing revenue from $5.6 million in 2022 to $11.2 million in 2024, representing a 41.8% CAGR. Currently operating from our Dallas plant, we are executing a disciplined geographic expansion strategy with planned facilities in South Carolina (2026) and Arizona/Nevada (2027), enabling us to serve a large percentage of the U.S. population. Our Products Our product portfolio consists of fresh citrus juice, fresh citrus-based line of lemonades and wellness shot offerings across multiple brand lines and retail customers, all produced using our cold chain process: Products (1) Buda Juice (Organic) Wellness shots in 2 oz format Available in 2-pack and 6-pack glass bottle configurations (2) Buda Fresh – Value-Forward Offering (Non-Organic) 12 oz Lime Juice, 16 oz

View Full Filing

View this S-1/A filing on SEC EDGAR

View on Read The Filing